Retatrutide: A Research Overview

Infographic: storage and handling practices commonly promoted for retatrutide research-peptide vials — freezer and refrigerator temperatures, amber vials, sterile handling, labelling

Key facts at a glance

  • What it is: an investigational once-weekly injectable from Eli Lilly that activates the GLP-1, GIP and glucagon receptors at once [1][2].
  • Approval status: not approved by any regulator anywhere, including SAHPRA, the FDA and the EMA [1][3].
  • Evidence so far: peer-reviewed Phase 2 trials in obesity and in type 2 diabetes [4][5], plus five positive Phase 3 readouts between December 2025 and July 2026 [1][6][7][8]. One of those, TRANSCEND-T2D-1 in type 2 diabetes, has since been published in The Lancet [9]; the other four have so far been reported only as company topline results.
  • Next milestones: a planned U.S. filing in Q1 2027 [1].
  • South Africa: SAHPRA treats online sale of unregistered GLP-1-class products as unlawful and has warned the public about them [3][10].

What retatrutide is

Retatrutide (Eli Lilly's internal code LY3437943) is an investigational, injectable molecule designed to activate three separate hormone receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor [1][2]. It is being developed by Eli Lilly and Company and, as far as we could verify, has not been approved by any medicines regulator anywhere in the world [1][11]. Lilly has not announced a brand name for it.

Why it is attracting attention

Retatrutide's glucagon-receptor activity is what distinguishes it from earlier incretin-class drugs such as semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). Glucagon signalling increases energy expenditure and promotes breakdown of stored liver fat, which researchers believe helps explain the unusually large weight reductions and liver-fat improvements reported in early trials [4][12]. That combination — reduced appetite, improved glucose and fat handling, and increased energy expenditure in a single weekly injection — is the scientific basis for the interest in this molecule, not a guarantee of any individual outcome.

The 2026 Phase 3 readouts intensified that attention: in the largest obesity trial so far, average weight loss in the top-dose group reached the high twenties in percentage terms at 80 weeks, a level Lilly compares with bariatric surgery [8]. Those figures are company-reported and not yet peer-reviewed.

Mechanism of action

Retatrutide combines three natural gut-hormone pathways in one molecule [1][2]:

  • GLP-1 receptor activity — the same pathway targeted by semaglutide — slows stomach emptying, increases fullness, and helps regulate insulin release after eating.
  • GIP receptor activity — partially shared with tirzepatide — is thought to improve fat-cell metabolism and insulin sensitivity alongside GLP-1 signalling.
  • Glucagon receptor activity increases energy expenditure and promotes breakdown of stored liver fat, and is thought to contribute to retatrutide's comparatively large effect on liver fat specifically [12].

Clinical development history and timeline

Phase 1 began in 2019 with a single-dose study in healthy volunteers (protocol J1I-MC-GZBA, NCT03841630 [13]). It found a mean half-life of about 6 days, supporting once-weekly administration, with treatment-related side effects, mainly gastrointestinal, becoming more common at higher doses, a transient rise in pulse rate and a short-lived fall in blood pressure [14]. A Phase 1b multiple-dose study in people with type 2 diabetes reported a similar half-life of about 6 days [15].

Phase 2 (ClinicalTrials.gov NCT04881760 [16]) was a randomised, placebo-controlled trial in 338 adults, published in the New England Journal of Medicine in 2023 [4]. In the highest-dose group, mean weight reduction reached roughly 17.5% at 24 weeks and 24.2% at 48 weeks, with weight still declining when treatment stopped — meaning the trial did not observe a plateau within its timeframe. A Phase 2a substudy of the same trial, in 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD), reported relative reductions in liver fat of up to about 82% at 24 weeks at the higher doses, with most participants on those doses reaching normal liver-fat levels [12].

Phase 3 is organised mainly as Lilly's TRIUMPH registrational programme: TRIUMPH-1 (obesity/overweight, with nested studies in knee osteoarthritis and sleep apnoea), TRIUMPH-2 (type 2 diabetes with obesity/overweight), TRIUMPH-3 (severe obesity with cardiovascular disease), TRIUMPH-4 (obesity with knee osteoarthritis), and TRIUMPH-Outcomes (a dedicated cardiovascular/kidney outcomes trial) [1][17]. A separate TRANSCEND-T2D programme studies retatrutide as a type 2 diabetes treatment [7]. Further Phase 3 studies target type 2 diabetes with renal impairment, chronic kidney disease, MASLD and chronic low back pain.

Phase 3 results reported so far

Between December 2025 and July 2026 Lilly announced topline results from five Phase 3 trials, all of which met their primary endpoints. The table summarises the headline weight figures Lilly reported for the highest dose in each trial, against placebo, using Lilly's "efficacy estimand" (which estimates the effect in people who stayed on treatment).

Company-reported Phase 3 topline results. Only TRANSCEND-T2D-1 has since been peer-reviewed.
Trial (announced)PopulationLengthAverage weight change, top dose vs placebo
TRIUMPH-4 (Dec 2025) [6]445 adults with obesity/overweight and knee osteoarthritis, no diabetes68 weeks−28.7% vs −2.1%; knee-pain (WOMAC) scores fell by up to about 76%
TRANSCEND-T2D-1 (Mar 2026) [7]Adults with type 2 diabetes managed by diet and exercise alone40 weeksUp to −16.8%; A1C lowered by up to 2.0 percentage points. Published in The Lancet (June 2026): 537 participants; −15.3% vs −2.6% on the treatment-regimen estimand [9]
TRIUMPH-1 (May 2026) [8]2,339 adults with obesity/overweight and a weight-related condition, no diabetes80 weeks (104-week extension)−28.3% vs −2.2%; −30.3% at 104 weeks in a blinded extension limited to 532 completers with a baseline BMI of 35 or more who tolerated their dose
TRIUMPH-2 (Jul 2026) [1]Adults with obesity/overweight and type 2 diabetes80 weeks−20.8% vs −4.0%; A1C lowered by up to 1.6 points
TRIUMPH-3 (Jul 2026) [1]Adults with severe obesity and established cardiovascular disease80 weeksUp to −22.6%

Two cautions apply. First, the "treatment-regimen" estimand, which counts everyone randomised including people who stopped treatment, gives lower numbers: for TRIUMPH-1 the trade press reported about 25.0% for the top dose versus 3.9% on placebo [18]. Second, apart from TRANSCEND-T2D-1, these are press-release figures; Lilly says full results will be presented at medical meetings and published in peer-reviewed journals [1]. People with type 2 diabetes consistently lost less weight than people without it, a pattern also seen with earlier incretin drugs.

Obesity, type 2 diabetes and other investigated indications

Beyond obesity and type 2 diabetes, indications under active Phase 3 investigation include cardiovascular risk reduction in people with obesity, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease/steatohepatitis, obstructive sleep apnoea, knee osteoarthritis pain, and chronic low back pain [17]. According to BioSpace's report of Lilly's Q2 2026 earnings call, the company says it has the data it needs for a first submission covering obesity, obstructive sleep apnoea and knee osteoarthritis pain [19]. None of these uses are approved anywhere; all remain investigational.

What the evidence does and does not show

Peer-reviewed evidence (the 2023 NEJM Phase 2 paper) establishes meaningful weight and metabolic effects over 48 weeks in a controlled trial of 338 people [4], and the first peer-reviewed Phase 3 paper, TRANSCEND-T2D-1, confirms glucose and weight effects over 40 weeks in 537 people with type 2 diabetes [9]. The Phase 3 topline results are consistent with that picture across larger, longer and more varied populations, which is a significant step. They do not yet establish long-term safety beyond the trial periods, effects on cardiovascular events (TRIUMPH-Outcomes has not reported), real-world effectiveness outside a monitored trial, or that any commercially sold "research peptide" product is the same material tested. Until the remaining Phase 3 papers are published, the topline figures above should be read as preliminary.

Known and observed adverse events

Across Phase 1 through Phase 3, the most consistently reported adverse events are gastrointestinal: nausea, vomiting, diarrhoea and constipation, generally dose-dependent and concentrated during dose escalation [4]. In TRIUMPH-1, Lilly reported nausea in up to 42.4% of retatrutide-treated participants versus 14.8% on placebo, and vomiting in up to 25.3% versus 4.8% [8]. Phase 1 data also showed a transient rise in pulse rate and a short-lived fall in blood pressure [14].

A signal specific to retatrutide is dysesthesia (abnormal skin sensations such as tingling, burning or numbness). In TRIUMPH-1 it occurred in 5.1–12.5% of treated participants depending on dose, versus 0.9% on placebo; TRIUMPH-4, in people with knee osteoarthritis, reported the highest rates so far: 8.8% and 20.9% at the 9 mg and 12 mg doses versus 0.7% on placebo [6]. TRIUMPH-2 and TRIUMPH-3 reported lower but still elevated rates. Lilly describes these events as generally mild to moderate and says most resolved during treatment [1][8]. Urinary tract infections were also somewhat more frequent than on placebo.

Discontinuation because of adverse events ranged from 4.1% to 11.3% across doses in TRIUMPH-1 (4.9% on placebo), reached 13.5% at the top dose in TRIUMPH-3 (4.8% on placebo) [1][8], and was 12.2% and 18.2% at the 9 mg and 12 mg doses in TRIUMPH-4 (4.0% on placebo), rates Lilly says were strongly linked to baseline BMI and included stopping for perceived excessive weight loss [6]. These are company figures; independent characterisation will come with peer-reviewed publication.

Regulatory status

Retatrutide has not been approved by the FDA, the EMA, or any other regulator we could identify. The only sanctioned ways to receive it are enrolment in one of Lilly's registered clinical trials [11] or Lilly's narrow pre-approval expanded-access programme, listed on ClinicalTrials.gov since mid-2026. That programme is for adults with refractory obesity (BMI of 35 or more despite the highest available dose of existing weight-management treatment) and two or more serious obesity-related complications who cannot join a trial, and access is requested by the treating physician [20]. Lilly says it is completing the chemistry, manufacturing and controls (CMC) data package and plans to submit a Biologics License Application to the U.S. FDA in Q1 2027, later than an earlier-signalled 2026 submission [1][21]. That is a company-stated intention, not a confirmed filing or approval date.

The filing route is contested. Lilly has been in litigation with the FDA since September 2024 over whether retatrutide counts as a protein-based biologic (reviewed under a BLA) or as a drug (reviewed under a New Drug Application). The FDA determined it is not a biologic; according to trade-press reports, a court vacated that determination but sent the "analogous to a protein" question back to the agency, and Lilly has appealed [19][22]. The outcome matters mainly for market exclusivity and could affect submission timing if the FDA refuses a biologics filing. It does not change retatrutide's current unapproved status either way. Assuming a standard review, press estimates put a first U.S. approval no earlier than late 2027 [11].

The growing grey market

Demand has run far ahead of approval. An observational study of de-identified U.S. health records by the data company nference, reported by Medscape in 2026, found that use of non-trial products sold as retatrutide grew about 1.8-fold per quarter from October 2023 to March 2026 [23]. Of 531 users whose supply route could be traced, 378 had obtained products outside a clinical trial, mostly from online or telehealth vendors and compounding pharmacies. In a matched comparison, 243 direct-to-consumer users lost an average of 7.2% of body weight at 6–12 months, compared with 15.5% for 89 trial participants, yet still showed the heart-rate rise characteristic of retatrutide. Some products were recorded as blends with other unapproved peptides. The study is observational and short, so it cannot prove cause, but it is the first real-world signal that grey-market "retatrutide" does not reliably behave like the trial drug.

Enforcement is increasing. The BBC reported that the UK's MHRA carried out raids and seizures of products claiming to contain retatrutide, and that Lilly had reported more than 14,000 websites, adverts and social-media posts it says illegally market the compound. Lilly's own position is that no one should take anything claiming to be retatrutide outside a Lilly-sponsored clinical trial [11].

South African regulatory context

SAHPRA (the South African Health Products Regulatory Authority) has published a general public warning about unregistered, compounded, substandard and falsified GLP-1 and GIP/GLP-1-class products sold online, on social media, and through informal channels in South Africa [3][24]. SAHPRA's position is that selling a registerable medicine that is not SAHPRA-registered is an offence under the Medicines and Related Substances Act, and that compounded products claiming GLP-1-class active ingredients have not been verified by SAHPRA for identity, purity or safety. SAHPRA-registered injectable GLP-1-class medicines include semaglutide, tirzepatide, dulaglutide and liraglutide [3][25]; retatrutide is not among them. SAHPRA's November 2024 statement goes further and names specific products sold as retatrutide — "Platinum Retatrutide", "Lira Retatrutide" and "Retatrutide iPharma" — among the falsified or unauthorised GLP-1-class products it found being sold online [3]. Its public information page on peptides adds that products bought from social media, online vendors, gyms or informal suppliers are likely counterfeit or substandard, and that powder forms of GLP-1 products are not registered [24].

In July 2026 the Mail & Guardian reported on a fast-growing local "shadow market" for retatrutide and related peptides sold online, through wellness clinics and in gyms [10]. SAHPRA's regulatory compliance manager told the paper that online sale is itself a red flag because it is not an authorised channel, that investigators had intercepted active ingredients smuggled in mislabelled as industrial chemicals and packaged into pens locally, and that anyone using retatrutide bought from an unofficial source should stop. South African doctors have issued similar warnings [26].

The wider GLP-1 enforcement climate is also tightening. In June 2026 the High Court in Pretoria granted Novo Nordisk an interim order stopping a local pharmacy group from compounding and selling unregistered semaglutide products, noting a SAHPRA inspection had found serious quality, safety and compliance deficiencies [27]. That case concerned semaglutide, not retatrutide, but it shows how South African courts and regulators are treating unregistered incretin-class products.

Clinical-trial evidence versus vendor marketing

It is worth being explicit about a distinction that vendor marketing routinely blurs: the weight-loss and safety figures reported above come from controlled clinical trials using material manufactured, stored and administered under Good Manufacturing Practice and direct regulatory oversight, in monitored populations, over defined periods. None of that chain of control applies automatically to a product bought from an online vendor, and the first real-world data on grey-market use suggest outcomes can differ substantially [23]. Citing a trial statistic on a product page — as some South African vendors do — provides context about the molecule; it is not evidence about the specific vial a buyer receives.

What "research peptide" marketing means

Vendors commonly label these products "research chemicals," "not for human consumption," or "for laboratory/research use only." This is a legal and marketing framing intended to position a sale outside medicines regulation — it is not a safety, purity, or quality designation. It does not mean a product has been verified for identity, purity, sterility or correct concentration, and it does not mean the product is equivalent to clinical-trial material. SAHPRA's own warnings make no exception for such labels: it states that any product intended to treat, prevent or alter bodily functions must be registered before it can be sold, and it names peptides commonly sold this way, such as BPC-157 and AOD-9604, as illegally marketed [24]. Our vendor scoring methodology treats a "research use only" disclaimer as a transparency signal about how a vendor frames its sale — never as evidence that a specific product is safe, pure, or authentic.

Why unverified products cannot be assumed equivalent

Without an independently verified, viewable Certificate of Analysis tied to the specific batch sold — checked against the named laboratory's own records — there is no way for a buyer or a reviewer to confirm that a vendor's product matches its labelled identity, purity or concentration. Even a genuine purity test does not cover sterility, endotoxins or how the product was stored and shipped. Our vendor reviews record, vendor by vendor, which sellers publish this kind of checkable testing evidence and which do not, and are explicit about which claims we could and could not independently verify.

Current timeline and what to watch next

  • Full peer-reviewed publication of the remaining Phase 3 trials, including formal characterisation of the dysesthesia signal.
  • Remaining Phase 3 readouts, including TRIUMPH-Outcomes and the kidney, liver and low-back-pain studies — treat any date as company-guided, not confirmed.
  • A ruling on Lilly's appeal, or a fresh FDA determination, in the biologic-versus-drug classification dispute [22].
  • Lilly's planned FDA submission in Q1 2027 [1].
  • Any EMA, MHRA or SAHPRA filings, none of which had a concrete public timeline in the sources we reviewed.

Frequently asked questions

Is retatrutide approved in South Africa?

No. Retatrutide is not registered with SAHPRA and is not approved by any regulator in the world. SAHPRA treats selling unregistered GLP-1-class products as an offence and has warned the public against buying them online.

When could retatrutide become available as a prescription medicine?

Lilly plans to file with the U.S. FDA in Q1 2027. A standard review would put a first U.S. approval no earlier than late 2027. No filing date has been announced for South Africa, so local availability would come later and is not guaranteed.

How much weight did people lose in the Phase 3 trials?

Lilly reported average losses of roughly 23–29% of body weight in the top-dose groups of its 68–80 week obesity trials, and about 21% in TRIUMPH-2, which enrolled people with type 2 diabetes. These are company topline results that have not yet been peer-reviewed, and they come from supervised trials using pharmaceutical-grade material.

What are the main side effects seen in trials?

Mostly gastrointestinal: nausea, diarrhoea, constipation and vomiting, usually during dose escalation. Trials also report a rise in heart rate and a retatrutide-specific signal of dysesthesia (tingling or burning skin sensations), which Lilly describes as generally mild to moderate.

Is "research peptide" retatrutide the same as the trial drug?

There is no way to know without batch-specific, independently verifiable testing, and even then sterility and handling are unknown. Early real-world data suggest grey-market products produced less than half the weight loss seen in trials. "Research use only" labels are a legal framing, not a quality guarantee.

Sources

← Back to the vendor ranking